Form 8-K - Current report:
SEC Accession No. 0001628280-25-001867
Filing Date
2025-01-17
Accepted
2025-01-17 17:17:07
Documents
13
Period of Report
2025-01-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 8-K flks-20250113.htm   iXBRL 8-K 24816
  Complete submission text file 0001628280-25-001867.txt   147465

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT flks-20250113.xsd EX-101.SCH 1807
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT flks-20250113_lab.xml EX-101.LAB 21689
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT flks-20250113_pre.xml EX-101.PRE 12543
15 EXTRACTED XBRL INSTANCE DOCUMENT flks-20250113_htm.xml XML 2725
Mailing Address 2450 HOLCOMBE BLVD SUITE J-608 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE J-608 HOUSTON TX 77021 346-772-0346
Salarius Pharmaceuticals, Inc. (Filer) CIK: 0001615219 (see all company filings)

EIN.: 465087339 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36812 | Film No.: 25539605
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)